4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
Ahan Chakraborty
Tue, September 1, 2026 at 8:26 PM GMT+5:30
7 min read
Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these conditions still lack approved treatments. The agency defines a rare disease as one affecting fewer than 200,000 people in the United States, a threshold that has supported a specialized regulatory framework and incentives for orphan-drug development
The scientific case is equally compelling. Many rare diseases are caused by genetic changes, making them suitable for targeted treatments such as RNA interference (RNAi), antisense oligonucleotides, enzyme replacement and gene therapy. Advances in molecular biology and genetic medicine are enabling drugmakers to target the root causes of these diseases instead of just managing symptoms. At the same time, the large collective patient population and high unmet need create significant commercial opportunities for therapies that can demonstrate meaningful clinical benefits.
Against this backdrop, Alnylam PharmaceuticalsALNY, BioMarin PharmaceuticalBMRN, Ultragenyx PharmaceuticalRARE and BridgeBio PharmaBBIO stand out. While their platforms differ, all four have commercialized therapies targeting rare or genetically defined disorders and are advancing additional programs to extend their growth runways. Their combination of established product revenue, pipeline catalysts and exposure to diseases with substantial unmet needs makes these stocks worth watching for long-term growth opportunities. All four companies currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alnylam Pharmaceuticals
Alnylam has built a leading RNAi franchise around genetically validated disease targets. Its commercial portfolio includes Amvuttra and Onpattro for hereditary transthyretin (ATTR) amyloidosis, Givlaari for acute hepatic porphyria and Oxlumo for primary hyperoxaluria type 1. Amvuttra is also approved for ATTR cardiomyopathy (ATTR-CM). In the first half of 2026, AMVUTTRA generated $1.90 billion in global net product revenue, up 137% year over year, while Givlaari and Oxlumo contributed $164.2 million and $103.4 million, respectively. Total product revenue increased 94% to $2.21 billion, driven primarily by higher demand for Amvuttra, particularly among U.S. ATTR-CM patients.
Year to date, ALNY shares have plunged 39.4% against the industry’s 8.7% growth
